Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Qiaohuan Deng"'
Autor:
Yanli Wang, Qiaohuan Deng, Zhenyue Gao, Guangwen Liu, Zhengjie Su, Yicheng Zhao, Lixiu Zhang, Haimiao Yang
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Purpose: The purpose of this study was to examine the pharmacokinetics (PK), bioequivalence and safety of generic sunitinib and its original product Sutent® in healthy Chinese subjects through a phase-I clinical trial.Methods: The study selected two
Externí odkaz:
https://doaj.org/article/9dc2df2f7bf24b7f81c35ac0ba2d6541
Autor:
Xinyao Qu, Qiaohuan Deng, Ying Li, Peng Li, Guangwen Liu, Yanli Wang, Zhengzhi Liu, Shuang Yu, Yang Cheng, Yannan Zhou, Jiahui Chen, Qing Ren, Zishu Yu, Zhengjie Su, Yicheng Zhao, Haimiao Yang
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
We conducted a phase I bioequivalence trial in healthy Chinese subjects in the fasting and postprandial states. The goal of this trial was to compare the pharmacokinetics and safety of the test preparation Cefaclor granule (Disha Pharmaceutical Group
Externí odkaz:
https://doaj.org/article/76895f33426b4f8ba1b8be343c10f533
Autor:
Guangwen Liu, Jinling Xue, Yanli Wang, Zhengzhi Liu, Xue Li, Dongmei Qu, Zhengjie Su, Kaibo Xu, Xinyao Qu, Zhaojuan Qu, Linlin Sun, Mingming Cao, Ying Wang, Xuesong Chen, Jing Yu, Lang Liu, Qiaohuan Deng, Yicheng Zhao, Lixiu Zhang, Haimiao Yang
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 149:2585-2593
Autor:
Zhongnan, Xu, Yanli, Wang, Guangwen, Liu, Jiahui, Chen, Wanhua, Wang, Yang, Cheng, Qing, Ren, Yingzi, Cui, Wei, Yang, Zhengzhi, Liu, Xuesong, Chen, Jinling, Xue, Tianying, Chang, Xinyao, Qu, Shuang, Yu, Yannan, Zhou, Kaibo, Xu, Zhengjie, Su, Qiaohuan, Deng, Yicheng, Zhao, Haimiao, Yang
Publikováno v:
Expert Opinion on Investigational Drugs. 31:737-746
Lenvatinib is a tyrosine kinase receptor inhibitor that inhibits vascular and endothelial growth factor receptor kinase activity. This study evaluated the bioequivalence and safety of lenvatinib with Lenvima® . The fasting and postprandial groups we
Autor:
Zhongnan Xu, Zhengzhi Liu, Yanli Wang, Jinling Xue, Tianying Chang, Yingzi Cui, Yang Cheng, Guangwen Liu, Wanhua Wang, Yannan Zhou, Shuang Yu, Qing Ren, Wei Yang, Xinyao Qu, Jiahui Chen, Xuesong Chen, Qiaohuan Deng, Haimiao Yang, Xiuge Wang
Glucagon-like peptide-1 (GLP-1) is an endogenous incretin hormone. Liraglutide, a GLP-1 receptor agonist, can lower blood sugar by increasing insulin production and inhibiting the production of glucagon. This study researched the bioequivalence and s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f658fea7a2ecda8480984bd6809976e5
Autor:
Zhongnan Xu, Yanli Wang, Zhengzhi Liu, Renjie Zhang, Yannan Zhou, Jing Yu, Jing Lan, Wenzhong Liang, Guangwen Liu, Xinyao Qu, Jiahui Chen, Zhengjie Su, Shuang Yu, Yang Cheng, Wanhua Wang, Qing Ren, Qiaohuan Deng, Yicheng Zhao, Haimiao Yang
Publikováno v:
International immunopharmacology. 109
Tofacitinib is an oral Janus kinase (JAK) inhibitor that has been marketed and approved in the USA for the clinical treatment of rheumatoid arthritis, psoriasis and other inflammatory and autoimmune diseases. A phase I clinical trial was conducted to
Autor:
Yang Cheng, Yingzi Cui, Wanhua Wang, Wei Yang, Shuang Yu, Qiaohuan Deng, Zhengzhi Liu, Haimiao Yang, Tianying Chang, Yanli Wang, Yan-Nan Zhou, Guangwen Liu, Zeyu Wang, Jiahui Chen, Jinling Xue, Qing Ren, Zhongnan Xu, Xinyao Qu
BACKGROUND Perjeta® is a recombinant, humanized monoclonal antibody that has been marketed and approved for the targeted therapy of human epidermal growth factor receptor (HER2) positive breast cancer in the United States. This study compared the bi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc6f03b689220fe14faa6bfba7d07e61